Næste

Automatisk afspilning

The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

2 Visninger • 07/18/23
Del
Indlejre
administrator
administrator
Abonnenter
0

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

Vis mere
0 Kommentarer sort Sorter efter
Facebook kommentarer

Næste

Automatisk afspilning